Skip to main content

Advertisement

Table 2 Univariate and multivariate analyses of 34 antibodies for DFS

From: Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial

Marker Category N (%) Univariate Multivariate
    Unadjusted Hazard Ratio (95%CI) P-value (Log-rank) Adjusted Hazard Ratio (95%CI) P-value(Wald)
AF6 Neg. 193 (23%)     
  Pos. 656 (77%) 0.86 (0.63 to 1.20) 0.386 0.87 (0.61 to 1.24) 0.437
Angiogenin Neg. 71 (7%)     
  Pos. 879 (93%) 1.06 (0.65 to 1.74) 0.803 1.01 (0.59 to 1.75) 0.967
Aurora A Neg. 585 68%)     
  Pos. 276 (32%) 1.41 (1.07 to 1.87) 0.015 1.32 (0.98 to 1.79) 0.070
BCL2 Neg. 377 (39%)     
  Pos. 580 (61%) 0.60 (0.47 to 0.78) <.001 0.82 (0.60 to 1.12) 0.217
α-Catenin Neg. 359 42%)     
  Pos. 501 (58%) 0.88 (0.67 to 1.16) 0.374 0.99 (0.73 to 1.34) 0.927
β-Catenin Neg. 265 (29%)     
  Pos. 636 (71%) 0.83 (0.63 to 1.11) 0.216 0.88 (0.64 to 1.21) 0.439
CAV1 Neg. 179 (19%)     
  Pos. 778 (81%) 1.39 (0.96 to 1.99) 0.077 1.16 (0.76 to 1.76) 0.495
CD10 Neg. 409 (45%)     
  Pos. 508 (55%) 1.19 (0.91 to 1.55) 0.199 1.20 (0.90 to 1.61) 0.211
CD44 Neg. 430 (61%)     
  Pos. 280 (39%) 0.83 (0.62 to 1.14) 0.264 0.90 (0.65 to 1.25) 0.524
CK5/6 Neg. 248 (27%)     
  Pos. 667 (73%) 0.88 (0.67 to 1.18) 0.414 0.98 (0.71 to 1.36) 0.921
CK8/18 Neg. 22 (2%)     
  Pos. 948 (98%) 0.30 (0.17 to 0.55) <.001 0.54 (0.28 to 1.03) 0.060
CK14 Neg. 774 (83%)     
  Pos. 158 (17%) 1.01 (0.71 to 1.42) 0.974 0.81 (0.55 to 1.19) 0.288
Cyclin D1 Neg. 316 (33%)     
  Pos. 648 (67%) 0.86 (0.66 to 1.13) 0.301 1.11 (0.81 to 1.51) 0.526
E-Cadherin Neg. 128 (13%)     
  Pos. 873 (87%) 1.09 (0.74-1.60) 0.653 0.98 (0.62-1.57) 0.937
EGFR Neg. 814 (81%)     
  Pos. 185 (19%) 1.02 (0.74 to 1.41) 0.895 0.72 (0.49 to 1.05) 0.090
ER Neg. 283 (26%)     
  Pos. 785 (74%) 0.53 (0.42 to 0.69) <0.001 0.90 (0.47 to 1.71) 0.744
FGFR1 Neg. 114 (15%)     
  Pos. 626 (85%) 1.36 (0.86 to 2.14) 0.189 1.60 (0.93 to 2.74) 0.087
FHIT Neg. 237 (26%)     
  Pos. 672(74%) 1.03 (0.76 to 1.40) 0.825 1.41 (0.98 to 2.01) 0.062
GATA3 Neg. 166 (17%)     
  Pos. 816 (83%) 0.70 (0.52 to 0.96) 0.027 0.83 (0.58 to 1.19) 0.311
HER2 Neg. 917 (84%)     
  Pos. 175 (16%) 1.64 (1.23 to 2.19) <0.001 1.12 (0.80 to 1.57) 0.493
Ki67 Neg. 661 (70%)     
  Pos. 280 (30%) 1.97 (1.51 to 2.56) <0.001 1.53 (1.12 to 2.08) 0.007
MET Neg. 602 (66%)     
  Pos. 315 (34%) 1.26 (0.97 to 1.65) 0.088 1.25 (0.93 to 1.66) 0.134
Moesin Neg. 824 (87%)     
  Pos. 118 (13%) 1.31 (0.91 to 1.89) 0.145 1.95 (.63 to 1.44) 0.815
MUC1 Neg. 95 (9%)     
  Pos. 938 (91%) 0.59 (0.42 to 0.86) 0.005 0.77 (0.51 to 1.16) 0.213
P21 Neg. 378 (41%)     
  Pos. 545 (59%) 0.93 (0.71 to 1.22) 0.616 0.84 (0.62 to 1.13) 0.241
P27 Neg. 175 (19%)     
  Pos. 768 (81%) 0.89 (0.65 to 1.24) 0.509 1.06 (0.75 to 1.50) 0.754
P53 Neg. 746 (75%)     
  Pos. 246 (25%) 1.59 (1.21 to 2.07) <.001 1.29 (0.95 to 1.75) 0.107
P-Cadherin Neg. 570 (61%)     
  Pos. 371 (39%) 1.44 (1.12 to 1.87) 0.005 1.31 (0.96 to 1.78) 0.089
PR Neg. 488 (46%)     
  Pos. 581 (54%) 0.54 (0.42 to 0.69) <0.001 0.66 (0.47 to 0.92) 0.013
PTEN Neg. 314 (34%)     
  Pos. 610 (66%) 1.00 (0.76 to 1.33) 0.977 1.00 (0.74 to 1.36) 0.991
TACC2 Neg. 148 (17%)     
  Pos. 723 (83%) 1.05 (0.73 to 1.52) 0.777 0.95 (0.64 to 1.42) 0.796
TACC3 Neg. 35 (6%)     
  Pos. 564 (94%) 1.83 (0.75 to 4.47) 0.179 1.17 (0.47 to 2.88) 0.738
TAU Neg. 685 (83%)     
  Pos. 141 (17%) 0.56 (0.36 to 0.88) 0.011 0.75 (0.47 to 1.21) 0.243
TOPO2A Neg. 199 (22%)     
  Pos. 714 (78%) 1.41 (0.99 to 2.00) 0.052 1.39 (0.93 to 2.07) 0.104